I find the company's behavior interesting lately....the main trials (P2) are all but completed (with P topline soon), there has been no mention of plans for additional trials starting, no PRs for quite a while compared to typical, and there have been staff reductions. IMHO this behavior points to Leo and Arthur being busy negotiating with BPs who are interested in our pipeline. While deals take time, I feel that there are patients who could benefit substantially from our drugs, so I hope whoever we partner with has some urgency to get these drugs moving along and commercialized. Only a few more weeks until the end of the 1st quarter!